TMCI Overview

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

Wall Street analysts forecast TMCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMCI is4.87 USD with a low forecast of 3.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Treace Medical Concepts, Inc revenue for the last quarter amounts to 47.20M USD, decreased -10.22

Treace Medical Concepts, Inc. EPS for the last quarter amounts to -0.28 USD, increased 12.00

Treace Medical Concepts, Inc (TMCI) has 450 emplpoyees as of June 20 2026.

Today TMCI has the market capitalization of 271.82M USD.